Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.70 -2.9%	$2.72	$1.07 ▼ $4.08	$373.36M	1.49	808,185 shs	568,412 shs
CNTB Connect Biopharma	$2.07	$1.39	$0.51 ▼ $2.86	$115.01M	-0.09	287,571 shs	69,893 shs
GOSS Gossamer Bio	$1.76 +1.1%	$1.51	$0.66 ▼ $2.23	$400.19M	1.96	3.50 million shs	3.07 million shs
PVLA Palvella Therapeutics	$40.90 +4.7%	$28.49	$11.17 ▼ $41.00	$452.19M	-0.01	187,830 shs	106,508 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	0.00%	-8.47%	-5.26%	+48.35%	+200.00%
CNTB Connect Biopharma	0.00%	+3.50%	+80.00%	+155.62%	+93.46%
GOSS Gossamer Bio	0.00%	-12.00%	+29.41%	+58.56%	+116.72%
PVLA Palvella Therapeutics	0.00%	+11.90%	+51.82%	+79.62%	+4,089,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	2.8701 of 5 stars	3.6	1.0	0.0	2.8	5.0	0.0
CNTB Connect Biopharma	3.0109 of 5 stars	3.8	3.0	0.0	3.3	2.5	0.0
GOSS Gossamer Bio	3.7988 of 5 stars	3.5	1.0	4.7	3.0	1.7	0.0
PVLA Palvella Therapeutics	2.544 of 5 stars	3.6	0.0	0.0	2.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.10	Buy	$12.67	369.14% Upside
CNTB Connect Biopharma	3.50	Strong Buy	$7.00	238.16% Upside
GOSS Gossamer Bio	3.00	Buy	$8.50	382.95% Upside
PVLA Palvella Therapeutics	3.09	Buy	$52.40	28.12% Upside

Current Analyst Ratings Breakdown

Latest CNTB, GOSS, CMPX, and PVLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
8/5/2025	PVLA Palvella Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$54.00
8/4/2025	PVLA Palvella Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$90.00
7/22/2025	CNTB Connect Biopharma	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$56.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	439.24	N/A	N/A	$0.91 per share	2.97
CNTB Connect Biopharma	$26.03M	4.42	N/A	N/A	$1.67 per share	1.24
GOSS Gossamer Bio	$114.70M	3.49	N/A	N/A	($0.20) per share	-8.80
PVLA Palvella Therapeutics	$42.81M	10.57	N/A	N/A	$5.58 per share	7.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.62	N/A	N/A	N/A	-344.81%	-1,774.72%	-46.73%	8/11/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/14/2025 (Estimated)

Latest CNTB, GOSS, CMPX, and PVLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	H1 2025	CNTB Connect Biopharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.81	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	-$0.17	+$0.01	-$0.17	$4.12 million	$11.49 million
5/15/2025	Q1 2025	CNTB Connect Biopharma	-$0.26	-$0.19	+$0.07	-$0.19	N/A	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	8.33	8.33
CNTB Connect Biopharma	0.01	10.25	10.25
GOSS Gossamer Bio	6.70	4.40	5.71
PVLA Palvella Therapeutics	N/A	8.84	8.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
CNTB Connect Biopharma	58.72%
GOSS Gossamer Bio	81.23%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
CNTB Connect Biopharma	22.60%
GOSS Gossamer Bio	6.70%
PVLA Palvella Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CNTB Connect Biopharma	110	55.56 million	43.00 million	Optionable
GOSS Gossamer Bio	180	227.38 million	212.15 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A

CNTB, GOSS, CMPX, and PVLA Headlines

Recent News About These Companies

Q2 Earnings Forecast for PVLA Issued By Lifesci Capital

August 8 at 2:17 AM | americanbankingnews.com

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

August 7 at 7:30 AM | globenewswire.com

Analysts Issue Forecasts for PVLA Q2 Earnings

August 7 at 6:46 AM | marketbeat.com

Palvella Therapeutics (PVLA) to Release Earnings on Wednesday

August 7 at 5:18 AM | marketbeat.com

Palvella Therapeutics initiated with an Outperform at Raymond James

August 6, 2025 | msn.com

Raymond James Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform Recommendation

August 6, 2025 | msn.com

Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at Lifesci Capital

August 6, 2025 | americanbankingnews.com

LifeSci Capital Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform Recommendation

August 5, 2025 | msn.com

Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated by Analysts at Lifesci Capital

August 5, 2025 | marketbeat.com

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 5, 2025 | globenewswire.com

Royce & Associates LP Invests $2 Million in Palvella Therapeutics, Inc. (NASDAQ:PVLA)

July 29, 2025 | marketbeat.com

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from Brokerages

July 28, 2025 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Truist Financial

July 21, 2025 | marketbeat.com

PVLA - Palvella Therapeutics Inc Sustainability - Morningstar

July 9, 2025 | morningstar.comM

Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin

July 9, 2025 | msn.com

Palvella Therapeutics, Inc. Added to Russell 3000® and Russell 2000® Indexes as of June 30, 2025

June 30, 2025 | quiverquant.comQ

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

June 30, 2025 | globenewswire.com

PVLA - Palvella Therapeutics Inc Key Metrics - Morningstar

June 27, 2025 | morningstar.comM

PVLA - Palvella Therapeutics Inc Executives - Morningstar

June 26, 2025 | morningstar.comM

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% | The ...

June 24, 2025 | manilatimes.netM

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by ... - Morningstar

June 24, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, GOSS, CMPX, and PVLA Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.70 -0.08 (-2.88%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.72 +0.01 (+0.56%)

As of 08/8/2025 07:59 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Connect Biopharma NASDAQ:CNTB

$2.07 0.00 (0.00%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.07 0.00 (0.00%)

As of 08/8/2025 06:27 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Gossamer Bio NASDAQ:GOSS

$1.76 +0.02 (+1.15%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.79 +0.03 (+1.70%)

As of 08/8/2025 07:54 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Palvella Therapeutics NASDAQ:PVLA

$40.90 +1.85 (+4.74%)

As of 08/8/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time